Semaglutide Weight Management and Cardiovascular Risk Reduction

Since ADA 2022, progress has been made across the Novo Nordisk pipeline Higher doses injectable sema ph. 2 initiation A American Diabetes Association. ND SCIENTIFIC 82" SESSIONS NEW ORLEANS, LA | JUNE 5-7,2022 Acquisition of Forma Therapeutics Inc. Ph. 1 initiated with once-weekly oral semaglutide Concizumab ph. 3 completion Ph. 1 trials initiated in NASH utilising the siRNA platform 2023 Oral Sema 25/50 mg ph. 3 results Sogroya® US approval FHD with cell therapy in heart failure and Parkinson's disease 83rd Scientific Sessions SAN DIEGO, CA/HYBRID JUNE 23-26, 2023 NNC6019 ATTR ph. 2 initiation NDec ph. 2 initiation CagriSema T2D CagriSema Ph. 3a ph. 2 completed initiated Mim8 Ph.3 treatment initiation Completion of final Icodec ph. 3 trial Ph. 3 initiated with semaglutide 7.2 mg Oral GLP-1/ GIP co-agonist ph. 1 completed Ziltivekimab HFPEF ph. 3 initiation Icodec submission Diabetes care: GLP-1 Diabetes care: Insulin Rare disease T2D: Type 2 diabetes; Sema: Semaglutide; Ph: Phase FHD: First human dose; siRNA: Silencing RNA; HfPEF: Heart failure with preserved ejection fraction Note: Timeline non-exhaustive Obesity care Oral semaglutide 50 mg ph. 3 read- out Other serious chronic disease Other

View entire presentation